Navigation Links
EMA Starts Formal Review of Glybera(R) Dossier
Date:1/25/2010

esults from its follow-up and ongoing studies, in accordance with reporting regulations.

About the Disease

LPLD is a seriously debilitating, and potentially lethal, orphan disease for which no treatment exists today. The disease is caused by mutations in the LPL gene, resulting in highly decreased or absent activity of LPL protein in patients. This protein is needed in order to break down large fat-carrying particles that circulate in the blood after each meal. When such particles, called chylomicrons, accumulate in the blood, they may obstruct small blood vessels. This can result not only in pancreatitis, but also in difficult-to-treat diabetes, and is associated with significant morbidity and mortality.

About Amsterdam Molecular Therapeutics

AMT, founded in 1998 and based in Amsterdam, is a leader in the development of human gene based therapies. Using AAV as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. This safe and efficacious proprietary platform offers a unique manufacturing capability which can be applied to a large number of rare (orphan) diseases that are caused by one faulty gene. Currently, AMT has a product pipeline with several AAV-based gene therapy products in LPL Deficiency, Hemophilia B, DMD, Acute Intermittent Porphyria and Parkinson's Disease at different stages of research or development.

For information

AMT will be presenting at the BioCEO & Investor Conference, Waldorf-Astoria, New York City, at 9:30 am (EST) on Tuesday, February 9, 2010.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and ex
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)
2. AMT Starts Preregistration Trial for Glybera(TM)
3. Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma
4. BioCis Pharma Starts Phase IIa Trial in Psoriasis
5. The Pittsburgh Life Sciences Greenhouse Starts 2009 With Investment Momentum
6. China Sky One Medical, Inc. Starts Production at Newly Acquired Facility and Reaffirms Guidance
7. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
8. Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics
9. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
10. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
11. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Denville, NJ (PRWEB) January 22, 2015 ... shearing technologies such as the Bioruptor® and complete ... semi-automation system for chromatin immunoprecipitation, alleviating the need ... reagents and controls needed for ChIP of histones ...
(Date:1/22/2015)... 22, 2015   GenoSpace , a precision medicine software company ... the broad use of genomic, imaging and other biomedical data ... Michelle Munson , CEO of Aspera, an IBM Company, ... - http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased ...
(Date:12/24/2014)... and NEW YORK , Dec. 24, ... company advancing patient care in critical areas, announced the closing ... stock, and warrants to purchase up to an aggregate 3,500,000 ... per share and $.01 per warrant.  The warrants have a ...
(Date:12/24/2014)... St. Louis, Missouri (PRWEB) December 23, 2014 ... Swiss biotechnology company, Syngenta, are in the process of being ... consolidated case is In Re: Syngenta AG MIR 162 Corn ... the District of Kansas. , Management of the Syngenta GMO ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... N.J., June 23 Informed Medical Communications,(IMC), ... for the,bio-pharmaceutical industry, today announced adoption of ... Dr. Jaime Nguyen as Medical,Director/ Compliance Officer ... the CO as well as methods for ...
... diaDexus, Inc.,today announced the release of ... Vol. 101, No 12A June 16, 2008 ... include testing for,lipoprotein-associated phospholipase A2 (Lp-PLA2), a ... cardiovascular disease,(CVD) risk assessment. These recommendations are ...
... Talk Will Cover the Use of Pharsight Software for ... ... June 23 Pharsight(R),Corporation (Nasdaq: PHST ), a ... optimizing clinical drug,development, today announced that Jason Chittenden, MS, ...
Cached Biology Technology:Informed Medical Communications Adopts Newly Enhanced Compliance Policy 2Expert Consensus Panel Recommendation for Incorporating Lp-PLA2 Testing into Cardiovascular Disease Risk Assessment Guidelines 2Expert Consensus Panel Recommendation for Incorporating Lp-PLA2 Testing into Cardiovascular Disease Risk Assessment Guidelines 3Expert Consensus Panel Recommendation for Incorporating Lp-PLA2 Testing into Cardiovascular Disease Risk Assessment Guidelines 4Pharsight to Present on IVIVC at Bioequivalence & Bioavailability Strategies Conference 2Pharsight to Present on IVIVC at Bioequivalence & Bioavailability Strategies Conference 3
(Date:1/22/2015)... January 22, 2015 , ... The European Patent Office to present a video retrospective ... nominations to be featured: Christofer Toumazou and Sophie ... finalists and winners of the Award   Starting on ...
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, ... to eliminate the pain of trying to remember their usernames ... biometrics fused to their smartphones. To assist people who have ... the company that created 1U and focuses on redefining identity, ...
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ( ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire ... http://photos.prnewswire.com/prnh/20130307/600769 Following ... the fingerprint reading feature with the iPhone 5S. It ...
Breaking Biology News(10 mins):Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 31U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2
... at the Centre for Stem Cell Research in Cambridge have ... ) a new and safer way of generating pluripotent stem ... every tissue of the body. Rapid developments in stem cell ... cell scientists to convert specialised cells, such as skin cells, ...
... the east coast of Australia, picturesque North Stradbroke Island ... the inhabitants of the island,s creeks and swamps are ... explains ecologist Robbie Wilson of the University of Queensland, ... they size each other up in a ritualistic display, ...
... has been estimated that in the United States, nearly ... livestock producers millions of dollars a year and resulting ... a University of Miami (UM) scientist and researchers from ... the first weather system advisory designed to improve the ...
Cached Biology News:Researchers piggyback to safer reprogrammed stem cells 2Crafty Australian crayfish cheat 2How cold is too cold for newborn calves? 2
... SELECT Stabilizer is an aqueous solution that ... non-toxic stabilizing chemicals in a saline solution, ... combination of 0.02% methylisothiazolone and 0.02% bromonitrodioxane ... is a diluent and stabilizer for biologically ...
AC input: 230 V...
A simple, sensitive and reliable method for determining free sulfhydryl content in peptides, protein...
... designed for stabilizing the coating biomolecules ... immunoassay development. It can stabilize ... and drying process and for long ... works as a blocking agent to ...
Biology Products: